Buy Marksans Pharma, says Akshata Deshmukh

Akshata Deshmukh, Chief Strategist-Trading at Networth Stock Broking told CNBC-TV18, "Marksans Pharma has been able to repay most of its Foreign Currency Convertible Bond (FCCB) liabilities, more than 90 percent which augurs well for the company."

She further added, "The cash flow generation is improving from the last fiscal and the company is into manufacturing of soft gelatin capsules which is supplied to the US. The company is doing pretty and going ahead with improved return ratios there could be re-rating of sorts. There is a potential of 15-20 percent from current levels. So the investors could look at even buying some more stock if one likes and the prospect definitely looks interesting in times to come."